BioSpace News Archive

Henry Schein, Inc. (Nasdaq: HSIC) announced that it is accepting applications for the Global Product Donation Program, which provides a broad variety of health care products and supplies to selected medical and dental nonprofit organizations to support their efforts to expand access to care for underserved communities.

Company’s continued product portfolio of innovation in telepathology and digital diagnostics accelerated by further investment

Pear Therapeutics Announces First Participant Enrolled in Virtual Real-World Study of Adults with Chronic Insomnia Fully virtual study will enroll 350 participants to collect real-world data for people with chronic insomnia using Pear’s own decentralized clinical trial infrastructure Engagement, Adherence, Healthcare Utilization, Medication Utilization, Health Economic Impact, and Clinical Outcomes in Sleep, Depression and Anxiety in People w

Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a late clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, today announced that it has appointed Todd Branning as Chief Financial Officer. Interim CFO, David Socks, will continue with the company as a strategic advisor and remain a member of the Board of Directors. Mr. Branning was most recently with Amneal Pharmace

Strategic partnership will focus on commercializing CELLSEARCH platform for COVID-19 related use cases, along with other COVID-19 related products

BioSerenity, a high growth company specializing in remote diagnostic solutions for Neurology, Sleep Medicine and Cardiology announces an article published in Epilepsy & Behavior describing deployment of innovative virtual clinics to provide improved access to care for people suffering from epilepsy. Healthcare access rem

ProtoKinetix, Incorporated ( www.protokinetix.com ) (the “Company” or “ProtoKinetix”) (OTCQB: PKTX ), a clinical-stage biomedical company, today announced an update to the Press Release of March 24, 2020 . The amendments to the clinical trial protocol have been submitted by the University of Alberta to Health Canada for their review. Upon approval from Health Canada and upon final approval by the University of Alberta

AnPac Bio-Medical Science Co., Ltd. (“AnPac Bio,” the “Company” or “we”) (NASDAQ: ANPC), a biotechnology company with operations in China and the United States focused on early cancer screening and detection, pre-announced certain results from the quarter ending 6/30/20. The Company performed 6,500 paid tests in June 2020, which was almost 50% higher than the average monthly paid tests in 2019. Based on unaudited numbers for the first half o

Italian clinical study finds combined strains of live bacteria reduced diarrhea and lessened progression of symptoms in hospitalized COVID-19 patients

Stereotaxis (NYSE: STXS), the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, today announced a publication in the European Heart Journal highlighting the benefits of Stereotaxis’ robotic technology in a COVID-19 patient. The publication concludes that catheter ablation “should be performed preferably with a remote navigation system in order to minimize the infectious risk of the staff of the electrop